¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"È¿"¿¡ ´ëÇÑ Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
5
ÄÚµå
¿µ¹®
ÇѱÛ
R89.0
Abnormal level of enzymes
ÀÌ»ó È¿¼Ò ¼öÄ¡
T44.4
Predominantly ¥á-adrenoreceptor agonists, NEC
´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁÖ·Î ¾ËÆÄ¾Æµå·¹³¯¸° ¼ö¿ëü È¿´ÉÁ¦
T44.5
Predominantly ¥â-adrenoreceptor agonists, NEC
´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁÖ·Î º£Å¸¾Æµå·¹³¯¸° ¼ö¿ëü È¿´ÉÁ¦
T45.3
Enzymes, NEC
´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È¿¼Ò
T46.4
Angiotensin-converting-enzyme inhibitors
¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦Á¦
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
5
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½